[EATG Global HIV News daily digest] Digest #33-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -






  




Latest Headlines




  Elvitegravir use similar in adolescents and adults
  Treatment Wednesday 24 February 2010
					
  
Once-daily elvitegravir — when added to a protease inhibitor-based
background regimen — may be as effective and tolerable in adolescents
as it is in adults, according to findings presented at the 17th
Conference on Retroviruses and Opportunistic Infections, held in San
Francisco. 
  SOURCE:
Pediatric SuperSite




  HIV not linked to earlier diagnosis for most cancers: presented at CROI
  Treatment Wednesday 24 February 2010
					
  
Researchers said here during the 17th Conference on Retroviruses and
Opportunistic Infections (CROI) that they could not find a link between
most cancers and a diagnosis of AIDS.
  SOURCE:
Doctor's Guide




  Hunterdon County man with HIV is accused of sex with juvenile
  World Policy Wednesday 24 February 2010
					
  
A Hunterdon County man who has spoken out about the importance of
people living with HIV practicing abstinence has been charged with
sexually assaulting a young girl while knowing he was infected with the
virus that causes AIDS.
  SOURCE:
NJ.com




  Experts recommend finetuning of HIV treatment
  Treatment Wednesday 24 February 2010
					
  
How quickly an HIV patient's immune system deteriorates may not affect
the outcome of the illness, a study has found, and this could help
change current guidelines for treatment of the disease.
  SOURCE:
REUTERS




  ViiV
Healthcare presents new data from HIV/AIDS portfolio demonstrating
research advances and commitment to patient care at Conference on
Retroviruses and Opportunistic Infections
  Treatment Wednesday 24 February 2010
					
  
Presentations include new data for S/GSK1349572, an integrase inhibitor in clinical development, SELZENTRY®, and EPZICOM®.
  SOURCE:
ViiV Healthcare




  Scientists unveil strategy to end HIV/AIDS within decades 
  Prevention Wednesday 24 February 2010
					
  
Health officials are considering a new strategy that they say could effectively kill off HIV/AIDS within 40 years.
  SOURCE:
SAgoodnews.co.za




  Advance reported in hepatitis C therapy
  Hepatitis Wednesday 24 February 2010
					
  
U.S. scientists say they've found two genetic alterations linked to an
enzyme deficiency that may help patients remain anemia-free during
hepatitis C therapy.
  SOURCE:
UPI.com




  HIV-positive man didn't warn up to 100 partners
  World Policy Tuesday 23 February 2010
					
  
Law requires people who could have AIDS to warn sexual partners.
  SOURCE:
WLKY.com




  Humanized mice come down with hepatitis B and C
  Hepatitis Tuesday 23 February 2010
					
  
Yet another group of lab mice have been "humanized" so researchers can
seek cures for infections that normally only strike people.
  SOURCE:
The Suncoast News




  Truvada and Norvir-boosted Reyataz more likely to cause bone loss in ACTG study
  Treatment Tuesday 23 February 2010
					
  
Compared with Epzicom, Truvada-treated patients had significantly
larger declines in spine and hip bone densities, whereas Norvir-boosted
Reyataz, compared with Sustiva, was associated with more significant
losses in spine BMD but not hip bone density. 
  SOURCE:
AIDSmeds.com




  Norvir-boosted Invirase linked to abnormal heart rhythms, FDA warns
  Treatment Tuesday 23 February 2010
					
  
The FDA suggests that people living with HIV using Norvir-boosted
Invirase talk with their health care professional about any questions
or concerns they have about Invirase. 
  SOURCE:
AIDSmeds.com




  Malarial parasite study identifies genes associated with drug resistance
  Tuberculosis & Malaria Tuesday 23 February 2010
					
  
The first genomewide association study of Plasmodium falciparum, the
parasite responsible for the most malarial deaths worldwide, has found
evidence of multiple phenotypes that influence drug resistance. 
  SOURCE:
Medscape Today




  Postpartum zidovudine/didanosine prevents NNRTI resistance mutations in HIV
  Treatment Tuesday 23 February 2010
					
  
Intra-partum nevirapine, given to prevent HIV transmission, contributes
to HIV resistance mutations to non-nucleoside reverse-transcriptase
inhibitors (NNRTIs) - but a one-month postpartum course of zidovudine
plus didanosine helps avoid this problem.
  SOURCE:
Medscape Today




  Progression of atherosclerosis is linked to inflammation in people with HIV 
  Treatment Tuesday 23 February 2010
					
  
People with HIV experience more rapid progression of atherosclerosis
than uninfected individuals, especially as measured in a specific part
of the carotid artery known as the bifurcation region.
  SOURCE:
Aidsmap




  HIV infection increases risk of bone fractures for men, but not for younger women 
  Treatment Tuesday 23 February 2010
					
  
A comparison of HIV-positive and HIV-negative male veterans found that
HIV infection conferred an independent but "modest" risk of fragility
fractures in the hip and spine. But a second study found that younger,
pre-menopausal women with HIV did not have an elevated risk of
fractures when compared to HIV-negative women of a similar age. 
  SOURCE:
Aidsmap




  Successful hepatitis C treatment reduces HIV disease progression and non-liver-related mortality 
  Hepatitis Tuesday 23 February 2010
					
  
HIV/HCV-co-infected people who achieve a sustained virological response
to interferon-based therapy not only reduce their risk of death due to
liver disease, but also experience less HIV disease progression and
have a lower rate of non-liver-related death.
  SOURCE:
Aidsmap




  Triglycerides linked to heart attack risk in D:A:D study 
  Treatment Tuesday 23 February 2010
					
  
The researchers suggested, however, that triglyceride levels have
limited prognostic value after taking cholesterol levels into account,
and therapies to reduce triglycerides are unlikely to address the
underlying problem. 
  SOURCE:
Aidsmap




  Many patients diagnosed with HIV today will have normal life expectancies, European studies find 
  Treatment Tuesday 23 February 2010
					
  
Two studies show that some groups of patients – those diagnosed
recently, or some of those with high CD4 counts when they begin
treatment – will have normal or near-normal life expectancies. 
  SOURCE:
Aidsmap




  Antiretroviral drugs have variable effects on bones and fat, lipoatrophy uncommon with modern regimens 
  Treatment Tuesday 23 February 2010
					
  
Different antiretroviral regimen components are linked to varying
changes in bone mineral density and body fat, according to a sub-study
of the US ACTG 5202 trial.
  SOURCE:
Aidsmap




  Studies confirm that drugs that penetrate brain control HIV better and improve symptoms of brain impairment 
  Treatment Tuesday 23 February 2010
					
  
A number of different studies confirmed that antiretrovirals that
penetrate the blood-brain barrier more fully are better at suppressing
HIV replication in the cerebrospinal fluid and help to improve symptoms
of neurological impairment. 
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100223/09b091e8/attachment-0001.html>